vs
Side-by-side financial comparison of HeartSciences Inc. (HSCS) and ORAMED PHARMACEUTICALS INC. (ORMP). Click either name above to swap in a different company.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
HSCS vs ORMP — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4K | $0 |
| Net Profit | $-2.4M | $10.0M |
| Gross Margin | 58.3% | — |
| Operating Margin | -85713.2% | — |
| Net Margin | -97179.4% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -12.9% | 198.2% |
| EPS (diluted) | $-0.85 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.4K | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | $0 | $2.0M | ||
| Q1 24 | $14.7K | — | ||
| Q4 23 | $3.9K | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | $0 | $674.0K |
| Q4 25 | $-2.4M | $10.0M | ||
| Q3 25 | $-2.1M | $48.4M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | $-2.5M | $-7.6M | ||
| Q1 24 | $-1.6M | — | ||
| Q4 23 | $-1.7M | $12.9M | ||
| Q3 23 | — | $-3.2M | ||
| Q2 23 | $-1.6M | $-1.2M |
| Q4 25 | 58.3% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.7% | ||
| Q1 24 | 69.0% | — | ||
| Q4 23 | 61.0% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -85713.2% | — | ||
| Q3 25 | -98637.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -225.0% | ||
| Q1 24 | -10376.7% | — | ||
| Q4 23 | -40254.9% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -562.5% |
| Q4 25 | -97179.4% | — | ||
| Q3 25 | -108157.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -382.1% | ||
| Q1 24 | -11182.4% | — | ||
| Q4 23 | -44830.2% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -177.2% |
| Q4 25 | $-0.85 | $0.25 | ||
| Q3 25 | $-1.58 | $1.13 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | $-2.57 | $-0.19 | ||
| Q1 24 | $-3.01 | — | ||
| Q4 23 | $-15.92 | $0.33 | ||
| Q3 23 | — | $-0.08 | ||
| Q2 23 | $-79.34 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0M | $51.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $199.7M |
| Total Assets | $6.0M | $230.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $51.4M | ||
| Q3 25 | $2.8M | $57.1M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | $2.6M | $3.7M | ||
| Q1 24 | $7.1M | — | ||
| Q4 23 | $100.1K | $66.8M | ||
| Q3 23 | — | $49.4K | ||
| Q2 23 | $1.7M | $943.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $74.5M | ||
| Q2 23 | — | — |
| Q4 25 | $4.2M | $199.7M | ||
| Q3 25 | $3.1M | $203.3M | ||
| Q2 25 | — | $154.5M | ||
| Q1 25 | $1.8M | $140.8M | ||
| Q1 24 | $8.6M | — | ||
| Q4 23 | $-1.6M | $163.8M | ||
| Q3 23 | — | $149.1M | ||
| Q2 23 | $230.6K | $151.5M |
| Q4 25 | $6.0M | $230.9M | ||
| Q3 25 | $6.4M | $220.5M | ||
| Q2 25 | — | $161.7M | ||
| Q1 25 | $5.7M | $147.5M | ||
| Q1 24 | $10.8M | — | ||
| Q4 23 | $2.4M | $220.6M | ||
| Q3 23 | — | $230.9M | ||
| Q2 23 | $3.3M | $156.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 0.50× | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-466.0K |
| Free Cash FlowOCF − Capex | — | $-468.0K |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.3M | $-466.0K | ||
| Q3 25 | $-2.0M | $-1.6M | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | $-1.6M | $-3.5M | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-988.2K | $-1.4M | ||
| Q3 23 | — | $-694.0K | ||
| Q2 23 | $-1.9M | $-2.6M |
| Q4 25 | — | $-468.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-3.5M | ||
| Q1 25 | — | $-3.5M | ||
| Q1 24 | $-2.1M | — | ||
| Q4 23 | $-990.1K | $-1.4M | ||
| Q3 23 | — | $-726.0K | ||
| Q2 23 | $-1.9M | $-2.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -176.1% | ||
| Q1 24 | -14352.1% | — | ||
| Q4 23 | -25388.2% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -393.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q1 24 | 59.8% | — | ||
| Q4 23 | 50.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 3.0% |
| Q4 25 | — | -0.05× | ||
| Q3 25 | — | -0.03× | ||
| Q2 25 | — | -0.27× | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -0.11× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
